Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented as a poster at ESMO Congress 2022.1
In a study of 133 patients who participated in the RALU trial, the median overall survival from the start of 177Lu-PSMA was 13.2 months overall, 12.0 months for patients who received 223Ra followed by chemotherapy and then 177Lu-PSMA, and 14.0 months for those who received chemotherapy followed by 223Ra and then 177Lu-PSMA.
During treatment with 177Lu-PSMA, investigators observed a 50% or greater decline in PSA in 42% of patients overall, 46% of those who received 223Ra followed by chemotherapy and then 177Lu-PSMA, and 36% of those who received chemotherapy followed by 223Ra and then 177Lu-PSMA.
“In patients for whom 223Ra had been used as part of routine disease management, subsequent 177Lu-PSMA therapy was clinically feasible and well tolerated, with acceptable myelosuppression rates,” Kambiz Rahbar, MD, of the University of Münster Medical Center in Münster, Germany, and colleagues concluded in the poster presentation.
The effectiveness of 177Lu-PSMA in patients previously treated with 223Ra was similar to other findings with 177Lu-PSMA, indicating no cross-resistance, according to Dr Rahbar and colleagues.
The study population had a median age of 73 years, and 56% had received 4 or more life-prolonging therapies, including abiraterone, enzalutamide, docetaxel, and cabazitaxel. All patients had bone metastases, and 27% had visceral metastases.
The latest findings echo those of a recently published real-world study led by Oliver Sartor, MD, of Tulane University School of Medicine in New Orleans, Louisiana.2 He and his collaborators examined the use of 177Lu-PSMA following 223Ra for bone-metastatic CRPC. The investigators reported their results in the Journal of Nuclear Medicine.
The median time between the treatments was 8 months. The median overall survival was 28 months from the start of 223Ra and 13.2 months from the start of 177Lu-PSMA. The authors acknowledged that their small sample size precludes definitive conclusions, but noted that their data, especially related to the duration of 177Lu-PSMA, suggest that the use of this medication after 223Ra is feasible in a real-world setting.
1. Rahbar K, Essler M, Eiber M, et al. Lutetium-177-prostate-specific membrane antigen therapy (177Lu-PSMA) in patients (Pts) with prior radium-223 (223Ra): Safety and effectiveness outcomes. Presented at ESMO 2022. September 9-13, 2022. Abstract 1392P.
2. Sartor O, la Fourgère C, Essler M, et al. 177Lu-Prostate-specific membrane antigen ligand after 223Ra treatment in men with bone-metastatic castration-resistant prostate cancer: Real-world clinical experience. J Nucl Med. 2022;63:410-414. doi:10.2967/jnumed.121.262240
This article originally appeared on Renal and Urology News